Modern Staging of Small Cell Lung Cancer

被引：52

作者：

Kalemkerian, Gregory P. ^{[1
]}

Gadgeel, Shirish M. ^{[2
]}

机构：

[1] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA

[2] Wayne State Univ, Deptartment Hematol & Oncol, Karmanos Canc Inst, Detroit, MI USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 01期

关键词：

POSITRON-EMISSION-TOMOGRAPHY; ASYMPTOMATIC BRAIN METASTASES; FDG-PET; LIMITED-DISEASE; INTERNATIONAL-ASSOCIATION; 7TH EDITION; SCLC; CLASSIFICATION; MANAGEMENT; PROPOSALS;

D O I：

10.6004/jnccn.2013.0012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For many years, small cell lung cancer (SCLC) has been staged using the Veterans Affairs classification system, which includes only 2 stages: limited (primary tumor and regional lymph nodes within a tolerable radiation field) and extensive (anything beyond limited stage). The TNM staging system used for non-small cell lung cancer is also prognostic for SCLC and should be integrated into the classification scheme for patients with SCLC. The staging workup for SCLC has traditionally included contrast-enhanced CT scans of the chest and abdomen, bone scan, and MRI or CT scan of the brain. Recent data suggest that PET can improve both staging accuracy and treatment planning in patients with SCLC, although further prospective studies are needed to fully define its role. (JNCCN 2013;11:99-104)

引用

页码：99 / 104

页数：6

共 32 条

[1]

American Joint Committee on Cancer, 2010, AJCC CANC STAGING HD, P299

[2]

[Anonymous], 1989, Lung Cancer, DOI DOI 10.1016/0169-5002(89)90156-6

[3] Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-d-glucose with positron emission tomography in patients with small cell lung cancer [J].

Arslan, Nuri ;

Tuncel, Murat ;

Kuzhan, Okan ;

Alagoz, Engin ;

Budakoglu, Burcin ;

Ozet, Ahmet ;

Ozguven, Mehmet Ali .

ANNALS OF NUCLEAR MEDICINE, 2011, 25 (06) :406-413

[4] High Impact of 18F-FDG-PET on Management and Prognostic Stratification of Newly Diagnosed Small Cell Lung Cancer [J].

Azad, Arun ;

Chionh, Fiona ;

Scott, Andrew M. ;

Lee, Szeting T. ;

Berlangieri, Sam U. ;

White, Shane ;

Mitchell, Paul L. .

MOLECULAR IMAGING AND BIOLOGY, 2010, 12 (04) :443-451

[5]

BENNETT D, 1989, CANCER-AM CANCER SOC, V63, P763, DOI 10.1002/1097-0142(19890215)63:4<763::AID-CNCR2820630426>3.0.CO

[6]

2-F

[7] Impact of positron emission tomography on the management of patients with small-cell lung cancer - Preliminary experience [J].

Blum, R ;

MacManus, MP ;

Rischin, D ;

Michael, M ;

Ball, D ;

Hicks, RJ .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (02) :164-171

[8] Positron emission tomography in limited-stage small-cell lung cancer: A prospective study [J].

Bradley, JD ;

Dehdashti, F ;

Mintun, MA ;

Govindan, R ;

Trinkaus, K ;

Siegel, BA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3248-3254

[9] Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer [J].

Brink, I ;

Schumacher, T ;

Mix, M ;

Ruhland, S ;

Stoelben, E ;

Digel, W ;

Henke, M ;

Ghanem, N ;

Moser, E ;

Nitzsche, EU .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (12) :1614-1620

[10] IS BONE-MARROW EXAMINATION IN SMALL-CELL LUNG-CANCER REALLY NECESSARY [J].

CAMPLING, B ;

QUIRT, I ;

DEBOER, G ;

FELD, R ;

SHEPHERD, FA ;

EVANS, WK .

ANNALS OF INTERNAL MEDICINE, 1986, 105 (04) :508-512

← 1 2 3 4 →